Marine Tessier

Marine Tessier

Auto-generated profile, based on publicly available information

Marine Tessier

Aix Marseille Univ, INSERM, INMED , 13273 Marseille , France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LBLaurie Baert
Laurie Baert
MBMahdia Benkhoucha
Mahdia Benkhoucha
NPNatalia Popa
Natalia Popa
MAMashal C. Ahmed
Mashal C. Ahmed
BMBenoit Manfroi
Benoit Manfroi
BHbertrand huard
bertrand huard

21 April 2023 in Brain
Verified
Journal Article
Open access
PDF file
MTMarine Tessier
Marine Tessier
MGMarta Saez Garcia
Marta Saez Garcia
EGEmmanuelle Goubert
Emmanuelle Goubert
EBEdith Blasco
Edith Blasco
ACAmandine Consumi
Amandine Consumi
CRClaudio Rivera
Claudio Rivera
Although the Na-K-Cl cotransporter (NKCC1) inhibitor bumetanide has prominent positive effects on the pathophysiology of many neurological disorders, the mechanism of action is obscure. Attention paid to elucidating the role of Nkcc1 has mainly been focused on neurons, but recent single cell mRNA sequencing analysis has demonstrated that the major cellular populations expressing NKCC1 in the cortex are non-neuronal. We used a combination of conditional transgenic animals, in vivo electrophysiology, two-photon imaging, cognitive behavioural tests and flow cytometry to investigate the role of Nkcc1 inhibition by bumetanide in a mouse model of controlled cortical impact (CCI). Here, we found that bumetanide rescues parvalbumin-positive interneurons by increasing interneuron-microglia contacts shortly after injury. The longitudinal phenotypic changes in microglia were significantly modified by bumetanide, including an increase in the expression of microglial-derived BDNF. These effects were accompanied by the prevention of CCI-induced decrease in hippocampal neurogenesis. Treatment with bumetanide during the first week post-CCI resulted in significant recovery of working and episodic memory as well as changes in theta band oscillations 1 month later. These results disclose a novel mechanism for the neuroprotective action of bumetanide mediated by an acceleration of microglial activation dynamics that leads to an increase in parvalbumin interneuron survival following CCI, possibly resulting from increased microglial BDNF expression and contact with interneurons. Salvage of interneurons may normalize ambient GABA, resulting in the preservation of adult neurogenesis processes as well as contributing to bumetanide-mediated improvement of cognitive performance.

1 January 2019 in Journal of Neuroscience Methods
Verified
Journal Article
Open access
CSCoralie Di Scala
Coralie Di Scala
MTM. Tessier
M. Tessier
CSC. Sapet
C. Sapet
FPF. Poulhes
F. Poulhes
FSF. Sicard
F. Sicard
CPChristophe Pellegrino
Christophe Pellegrino
Gene delivery within the central nervous system at postnatal age is one of the most challenging tasks in neuroscience and currently only a few effective methods are available. For postnatal central nervous system cells, viral approaches are commonly used for genetic engineering but they face several biosafety requirements for production and use making them less accessible to the community. Conversely, lipid-based methods are widely used in cell culture but face limitation in vivo mainly due to the inflammatory responses they induce. To this aspect, the use of a transgenic mouse line can represent a credible answer to the community working on rat models still requires an effective and successful solution to circumvent these difficulties. We describe a new polymer-based gene delivery system allowing persistent and robust in vivo transfection with low DNA amount, reduced inflammation and high diffusion. The expression profile along the brain, the stability, the diffusion of the DNA together with the quantity of cells transfected were evaluated through in vivo approaches. With a single low-volume injection, we targeted different cell types within the rat brain. We measured the diffusion rate ranging from 1 to 5 mm based on the injected volume, in the three-dimensions axis. Finally, we modified brain susceptibility to epileptic seizures using a specific knock-down of the neuronal specific potassium-chloride transporter 2. This safe and easy system opens perspectives for non viral gene delivery in the rat brain with perspectives to study brain function in vivo.

5 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMarine Tessier
Marine Tessier
MGMarta Saez Garcia
Marta Saez Garcia
EGEmmanuelle Goubert
Emmanuelle Goubert
LTLi Tian
Li Tian
FMFlorence Molinari
Florence Molinari
CRClaudio Rivera
Claudio Rivera
Objective: The Na-K-Cl cotransporter (NKCC1) inhibitor bumetanide has prominent positive effects on the pathophysiology of many neurological disorders. Here we studied whether bumetanide could influence post-traumatic cognitive decline and inflammatory processes by regulating astrocyte and microglia activation. Method: Controlled cortical impacted (CCI) animals were treated with bumetanide during the first post-CCI week. Immunochemistry, flow cytometry, immunoassay, and in vivo imaging were used to study astrocytic and microglial morphology and phenotype as well as adult neurogenesis. Telemetric electroencephalograms and cognitive behavioral test were performed at one-month post CCI. Results: Bumetanide prevented CCI-induced decrease in hippocampal neurogenesis and parvalbumin positive interneuron loss. Deletion of NKCC1 in astrocytes neither rescued interneurons nor promote neurogenesis. Interestingly, bumetanide had a strong effect on microglial activation by inducing polarization towards the M1-like phenotype 3 days post-CCI and the M2-like phenotype 7 days post-CCI. Bumetanide increased microglial Brain-derived neurotrophic factor (BDNF) expression and interaction with parvalbumin interneurons. The early treatment with bumetanide resulted in improvements in working and episodic memory, one-month post-CCI, as well as the normalization of theta band oscillations. Interpretation: Here, we disclose a novel mechanism for the neuroprotective action of bumetanide mediated by an acceleration of microglial activation dynamics that leads to an increase of parvalbumin interneuron survival following CCI, possibly resulting from increased microglial BDNF expression and contact with interneurons. Salvage of interneurons may normalize ambient gamma-aminobutyric acid (GABA) resulting in the preservation of adult neurogenesis processes as well as contributing to bumetanide-mediated improvement of cognitive performance.

15 October 2025 in bioRxiv
Verified
Preprint
Open access
MTMarine Tessier
Marine Tessier
ZHZeinab Hamze
Zeinab Hamze
NBNathalie Bonello-Palot
Nathalie Bonello-Palot
NRNathalie Roeckel-Trévisiol
Nathalie Roeckel-Trévisiol
SAShahram Attarian
Shahram Attarian
NBNathalie Bernard-Marissal
Nathalie Bernard-Marissal
Charcot-Marie-Tooth disease type 2A (CMT2A) is the most common axonal CMT and is associated with an early onset and severe motor-dominant phenotype. CMT2A is mainly caused by dominant mutations in the MFN2 gene, encoding Mitofusin-2, a GTPase located in the outer membrane of the mitochondria and endoplasmic reticulum (ER). Mutations in MFN2 are known to affect mitochondrial dynamics. We previously demonstrated that the mutated MFN2 Arg94Gln further disrupts contacts between the ER and the mitochondria, leading to progressive axonal degeneration. There is no effective therapeutic approach to slow or reverse the progression of CMT2A, and treatments currently under development primarily focus on restoring mitochondrial function. Here, we provide proof-of-concept that neuronal overexpression of wild-type MFN2 (MFN2 WT ) provides therapeutic benefit in transgenic CMT2A mice carrying the mutated MFN2 Arg94Gln . Intrathecal delivery of an AAV9 vector expressing MFN2 WT effectively targets motor and sensory neurons, restoring ER-mitochondria contacts and mitochondrial morphology, thereby preserving both neuromuscular junction integrity and motor function. Strikingly, therapeutic efficacy is also achieved following vector injection after the onset of symptoms, rescuing the molecular hallmarks of CMT2A pathology and reversing locomotor. Notably, AAV administration was well tolerated, with no evidence neither of hepatotoxicity nor dorsal root ganglion inflammation. These results establish that boosting MFN2’s levels using gene therapy is a promising therapeutic avenue for CMT2A.

6 April 2026
Verified
Thesis
Closed access
MTMarine Tessier
Marine Tessier
La bumétanide, un inhibiteur du cotransporteur Na-K-Cl, a des effets positifs sur la physiopathologie de nombreux troubles neurologiques. L’objectif de mon travail a été d’étudier la cinétique de la réaction inflammatoire se mettant en place après un traumatisme crânien (TC). Ensuite, d’étudier si ce traitement pouvait influencer ce processus inflammatoire, dans le but d’améliorer les troubles mnésiques dont souffrent les patients dans la phase chronique d’un TC. Pour cela, des animaux ayant subi un impact cortical contrôlé (CCI) ont été traités à la bumétanide pendant la première semaine post-traumatique. J’ai utilisé des techniques immunohistochimiques, de cytométrie en flux et d’ELISA afin d’étudier la neurogenèse adulte ainsi que la morphologie et le phénotype des astrocytes et de la microglie. J’ai observé la motilité des cellules microgliales avec de l’imagerie in vivo. Enfin, j’ai posé des EEG télémétriques et réalisé des tests comportementaux pour étudier les conséquences sur la connectivité du cerveau et l'impact sur les performances cognitives. Nous avons montré que le déséquilibre de la neurogenèse adulte dans l'hippocampe et la perte massive d'interneurones induit par le CCI est contré par la bumétanide. Nous montrons que cela pourrait être lié à l’augmentation de la production de BDNF par la microglie, et à l’augmentation du nombre de contacts avec les interneurones. La bumétanide permet enfin d’empêcher l’apparition de troubles mnésiques et les modifications de la bande thêta dans la phase chronique.